top of page

on the pen doesn't exist without your


I'm Dave. On The Pen is my thing. My passion. But so are my 4 kids, and so is my day job. In order to sustain my efforts, I have to cover the costs involved with OTP. The website, the programs that make it pretty, and the tools that help people connect to it. A gift of ANY amount is greatly appreciated!

Untitled design (4).png

Wegovy Protects The Heart, Does Zepbound Also?

Recent updates from Novo Nordisk's SELECT trials have unveiled groundbreaking data about Wegovy, a medication primarily known for its effectiveness in weight management. The active ingredient in Wegovy, a GLP-1 receptor agonist, is now also showing promising cardiac protective properties, independent of weight loss! This revelation could significantly impact the treatment landscape for patients with heart disease, those at risk of heart failure, or even as a preventive measure in cardiac health.

Understanding the Impact on Heart Disease and Heart Failure

The SELECT trial data suggests that the benefits of Wegovy go beyond weight loss. The medication's ability to offer cardiac protection opens a new chapter in managing heart health, particularly for those with existing heart conditions or those who are at high risk of developing such issues. For patients battling heart disease or heart failure, Wegovy’s use could potentially improve heart function, reduce the incidence of heart attacks, and possibly slow the progression of heart-related ailments.

This is particularly significant because heart disease remains one of the leading causes of death globally. Traditional treatment methods focus on managing symptoms and underlying causes such as high cholesterol, hypertension, and obesity. Wegovy's ability to add a layer of heart protection offers a dual benefit: managing weight and directly contributing to cardiac health.

Prophylactic Use in Cardiac Health

For individuals at risk of heart disease but not yet diagnosed, the implications of these findings are equally transformative. Incorporating Wegovy as part of a prophylactic regimen could help reduce the risk of developing heart conditions, especially for those with predisposing factors such as obesity, a sedentary lifestyle, or a family history of heart disease.

Broader Implications for Other GLP-1 Agonists

The positive outcomes of Wegovy could extend to other medications in the GLP-1 receptor agonist class. These drugs, generally prescribed for diabetes management and weight loss, might also possess inherent properties that protect against heart disease. Of course this is not necessarily a one for one or complete apples to apples comparison when looking at medications like Mounjaro or Zepbound. The active ingredient in those medications is Tirzepatide, a 5x strong GIPr agonist vs GLP-1. While it is likely that Tirzepatide offers similar benefits, we will know much more when we see full readouts on the SURPASS-CVOT outcomes later this year. These findings will open up potential for broader use in cardiovascular health management, encouraging further research and possibly new indications for GLP-1 agonists.

A Potential Paradigm Shift in Cardiac Care

The implications of the SELECT trials could lead to a paradigm shift in how we approach the prevention and treatment of heart conditions. As we continue to unpack the full scope of GLP-1 receptor agonists' benefits, it is essential for healthcare providers to consider these medications not just for metabolic syndrome management but also as a significant component of cardiovascular care.

For patients, this development is a beacon of hope—offering not just a solution for weight loss but a protective shield for their hearts. Moving forward, it will be crucial to integrate these findings into clinical practice, enhancing patient outcomes across the spectrum of heart health and beyond.

This revelation underscores the importance of ongoing research and innovation in the pharmaceutical industry, highlighting how medications can evolve in their applications and impact on public health.

326 views0 comments

Recent Posts

See All


bottom of page